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Summary The monoclonal antibody (MAb) G250 binds to a tumour-associated antigen, expressed in renal
cell carcinoma (RCC), which has been demonstrated to be a suitable target for antibody-mediated
immunotherapy. A bispecific antibody having both G250 and anti-CD3 specificity can cross-link G250
antigen-expressing RCC target cells with T cells and can mediate lysis of such targets. Therapy studies with
murine antibodies are limited by immune responses to the antibodies injected (HAMA response), which can be
decreased by using chimeric antibodies. We generated a chimeric bispecific G250/anti CD3 MAb by
transfecting chimeric genes of heavy and light chains for both the G250 MAb and the anti-CD3 MAb into a
myeloma cell line. Cytotoxicity assays revealed that the chimeric bispecific MAb was capable ofmediating lysis
of RCC cell lines by cloned human CD8+T cells or by IL-2-stimulated peripheral blood lymphocytes (PBLs).
Lysis mediated by the MAb was specific for target cells that expressed the G250 antigen and was effective at
concentrations as low as 0.01 pg ml-'. The chimeric bispecific G250/anti-CD3 MAb produced may be an
effective adjuvant to the currently used IL-2-based therapy of advanced renal cell arcinoma.
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Targeting cytotoxic effector cells for localisation in tumours
has been pursued as an attractive therapeutic option. One
approach is the use of bispecific monoclonal antibodies that
can cross-link tumour cells with activation-related molecules
on effector cells, such as the CD3 complex on cytotoxic T
lymphocytes (CTLs) or with Fc receptors on monocytes and
natural 'killer (NK) cells (Fanger et al., 1990). Cross-linking
of CD3 by bispecific antibodies can redirect the specificity of
activated T lymphocytes and circumvents MHC restriction
(Garrido et al., 1990; Berg et al., 1991; Brissinck et al., 1991;
Qian et al., 1991; Nistico et al., 1992). It has been shown that
intravenously administered bispecific MOvl8/anti-CD3 (OC/
TR) MAb, recognising both the ovarian carcinoma-
associated antigen MOv18 and the CD3 complex, can
localise in tumours in patients (Tibben et al., 1993). Targeted
T lymphocytes, bearing bispecific antibody bound to their
CD3 complex, may accumulate in the tumour, whereas any
bispecific MAb binding to tumour cells first (Van Dijk et al.,
1991), may subsequently attract circulating T cells.
Monoclonal antibody (MAb) G250 recognises an antigen
expressed on human renal cell carcinoma (RCC, Oosterwijk
et al., 1986). Whole immunoglobulin molecules and F(ab)2
fragments of the G250 MAb localised preferentially in
tumours, both in model studies with RCC xenografted nude
mice and RCC patients, and were suitable for tumour
visualisation in mice (Van Dijk et al., 1988, 1991) and in
patients (Oosterwijk et al., 1993). Therapeutic effects of
murine G250 IgG2a were demonstrated by tumour growth
inhibition studies in nude mice xenografted with RCC (Van
Dijk et al., 1994). The G250 antigen can therefore be
considered a suitable target for antibody-mediated immu-
notherapy. Murine bispecific G250/anti-CD3 antibody has
previously been generated and was shown to induce lysis of
RCC cell lines by IL-2-activated human CTLs in vitro (Van
Dijk et al., 1989). In nude mice F(ab)2 fragments of the
murine bispecific G250/anti-CD3 MAb localised well in
xenografted RCC (Van Dijk et al., 1991).
To cure established RCC will require intensive treatment
with multiple MAb injections over an extended period.
Repeated administration of murine antibodies to patients
frequently elicits a human anti-mouse antibody (HAMA)
response (Courtnay-Luck et al., 1986; Schroff et al., 1985;
Shawler et al., 1985; Saleh et al., 1993; Riva et al., 1993).
Chimeric antibodies, in which the murine constant regions of
the heavy and light chain are replaced by those of human
origin, are less immunogenic and have a longer serum half-
life than murine antibodies (LoBuglio et al., 1989; Meredith
et al., 1991). The strong immunogenicity of murine G250 and
anti-CD3 MAbs observed in patients, was absent when the
chimeric versions of these antibodies were injected (Oos-
terwijk et al., 1993; Canevari et al., 1995; E Oosterwijk,
personal communication; Coney et al., 1996). Based on the
observation that chimerisation abrogates the immunogenicity
of the parental G250 and the anti-CD3 MAb in patients, we
expect the chimeric bispecific G250/anti-CD3 MAb to be
non-immunogenic.
We generated a chimeric version of the bispecific G250/
anti-CD3 antibody to enable treatment of patients with the
bispecific G250/anti-CD3 MAb. To this end the non-
immuno-globulin-producing myeloma cell line, P3X-
63Ag8.653, was transfected with expression vectors encoding
the chimeric heavy and light chains of the anti-CD3 and the
G250 antibody. Transfectants that produced bispecific
antibody were selected and were used for antibody
purification. The chimeric bispecific antibody was found to
bind specifically to the G250 antigen expressed on RCC cell
lines and to CD3 on human T lymphocytes. In vitro
cytotoxicity assays showed that the chimeric bispecific
G250/anti-CD3 MAb is capable of inducing lysis of G250-
positive RCC cell lines by IL-2-activated human T
lymphocytes as well as peripheral blood lymphocytes (PBLs).
Materials and methods
Cell lines
The non-immunoglobulin-producing murine myeloma cell
line P3X63Ag8.653 (ATCC CRL 1580) and the T cell line
HPB-ALL were cultured in Iscove's modified Dulbecco's
medium supplemented with 2 mM L-glutamine and 5% heat-
inactivated fetal calf serum (FCS). The human RCC cell lines
A704 (ATCC HTB45), ACHN (ATCC CRL1611), SK-RC-1,
SK-RC-7 and SK-RC-45, obtained from the Sloan Kettering
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Memorial Institute (NY, USA), were cultured in Dulbecco's
modified Eagle medium (DMEM) supplemented with 10%
FCS and penicillin/streptomycin (P/S, GIBCO-BRL Life
Technologies, Breda, The Netherlands). Adherent cells were
passaged at confluence with 0.5% trypsin and 0.01% EDTA.
The human CD3+CD8+T cell clone, TIL 7.9, was derived
from tumour-infiltrating lymphocytes of a cervical carcinoma
(kindly provided by W van Driel, Leiden, The Netherlands).
The TIL7.9 cells were cultured in 96-well round bottom
microtitre plates in RPMI-1640 medium containing 10%
human AB serum, P/S, 4 mM L-glutamine, 1 jg ml-1
leucoagglutinine, 1 jug ml-' indomethacine, 10 U ml-' IL-2
(Eurocetus, Amsterdam, The Netherlands) in the presence of
feeder cells irradiated with 30 Gy. The feeder cell population
contained the EBV-transformed human B cell lines, APD and
BSM (kindly provided by Dr R Bolhuis, Rotterdam, The
Netherlands), pooled human PBLs and the autologous
cervical carcinoma cell line, CSCC-7, at concentrations of
20 000 cells per well for PBLs and 5000 cells per well for the
B cell lines and tumour cells respectively. The transfectoma
cell lines anti-CD3 4B5, producing chimeric anti-CD3 MAb,
and chG250 7C1, producing chimeric G250 MAb, were
kindly provided by Centocor (Leiden, The Netherlands), and
were cultured in RPMI mixed with DMEM in a 1:1 volume
ratio, supplemented with 10% FCS, P/S, 4 mM L-glutamine
and 0.02 mM P-mercaptoethanol.
Expression vectors
Expression vectors containing the chimeric heavy and light
chain genes for the G250 MAb, pSV2gptHGI-G250 (chimeric
heavy chain vector) and pSV2gptHCKG250 (chimeric light
chain vector), and the anti-CD3 MAb, pSV2gptHGI-CD3
(heavy chain) and pSV2neoHCKCD3 (light chain), had
previously been constructed (Coney et al., 1996). The
chimeric genes were composed of the murine VH and VK
regions connected to the human CH and CK regions
respectively. The anti-CD3 coding genes had previously
been derived from the OC/TR cell line, described by
Mezzanzanica et al. (1988). The pSV2neoHCKCD3 vector
contained the neo gene for selection of G418 resistant
transfectants. The other vectors contained the xanthine
guanine phosphoribosyl transferase (gpt) gene, that confers
resistance to mycophenolic acid after transfection into
mammalian cells. To construct a double plasmid,
pSV2gptHGl-G250/HCKG250, containing the chimeric G250
IgGl heavy as well as the light chain genes, the 10 kb Sall
restriction fragment from pSV2gptHCKG250, containing the
chimeric light chain gene construct, was isolated and inserted
into the Sall site of pSV2gptHCKG250. The presence of the
insert and its orientation with respect to the chimeric heavy
chain gene was checked by restriction analysis with Sall,
XhoI/EcoRI and EcoRI/EcoRV restriction enzymes (Figure
1).
Transfections
An aliquot of 10 jug of pSV2gptHGI-CD3 and
pSV2neoHCKCD3 plasmid DNA was linearised by digestion
with respectively KpnI and BamHI endonucleases, extracted
with chloroform/phenol, ethanol precipitated and dissolved in
sterile water at a final concentration of 1 jg jl-1.
pSV2gptHGI-CD3 was additionally digested with EcoRV to
cleave out a 250 bp fragment, which inactivates the gpt gene.
Recipient myeloma P3X63Ag8.653 cells were seeded at a
density of 2 x105 cells ml-' 24 h before transfection. Cells
were washed twice in Hanks', balanced salt solution (BSS)
and resuspended at 2 x 107 cells ml-'. An aliquot of 10 jul of
pSV2gptHGI-CD3 was mixed with 10 jul pSV2neoHCKCD3 in
a prechilled cuvette and 1 ml of cells was added. Cells were
electroporated at 200 V and 960 juF in a BioRad Gene Pulser
(BioRad, Melville, NY, USA). The cell suspension was
diluted with 9 ml of cold culture medium and incubated on
ice for 30 min. Living cells were counted and plated out in
G250 VH
E Ck E E G250Vk
10 kb fragment from pSV2gptHCkG250
Figure 1 Expression vector containing the chimeric heavy and
light chain genes of the GB250 MAb. pSV2gptHGl-G250/
HCKG250 was constructed by inserting the lOkb Sal I fragment
from pSV2gptHCKG250 containing the chimeric gene encoding
the G250 MAb light chain into the Sal I (S) site of pSV2gptHGl-
G250 (G250 heavy chain expression vector). The orientation of
the insert was checked by restriction analysis with XhoI (X) and
EcoRI (E) or EcoRI and Eco RV (RV). The numbers in the figure
indicate the distance (kb) between the restriction sites. Amp,
ampicillin.
flat bottom 96-well microtitre plates at a density of 10 000,
5000 and 2500 cells per well. Cells were cultured at 37°C and
5% carbon dioxide for 48 h, followed by the addition of
G418 (0.5 mg ml-'). G418-resistant transfectants were
screened for chimeric antibody production by ELISA after
2 weeks and the transfectant that produced the highest levels
of chimeric anti-CD3 MAb was retransfected with 10 ug
XhoI-linearised pSV2gptHGl-G250/HCKG250 double plas-
mid. Transfectants were selected in medium containing
0.25 jg ml-' mycophenolic acid, 1.25 jug ml-' hypox-
anthine, 25 jug ml-' xanthine and 0.5 mg ml-1 G418.
Production of chimeric G250 MAb was analysed by
ELISA. The transfectant with the highest yield of chimeric
G250 MAb, as determined by ELISA, was cloned by limiting
dilution and clones were assayed for chimeric G250 MAb
production by ELISA. The production of chimeric bispecific
MAb was analysed by flow cytometry and the functionality
of the chimeric bispecific MAb was tested in a cytotoxicity
assay. Stability of antibody production was determined after
2 months of culture by determining the percentage of
bispecific MAb producing subclones after a limiting dilution
cloning.
ELISA
For detection of chimeric anti-CD3 antibody in the medium
of the transfectants, ELISA plates, coated at 4°C for 24 h
with 1 jug per well goat anti-human IgG, Fc fragment-specific
(Jackson ImmunoResearch Laboratories, Westgrove, PA,
USA) in coating buffer (15 mM sodium carbonate, 35 mM
sodium bicarbonate pH 9.55), were washed with phosphate-
buffered saline (PBS), 0.05% Tween and incubated with 50 jl
of culture supernatant of the transfectants for 1 h at room
temperature. Plates were washed and incubated with 50 jul
per well alkaline phosphatase-conjugated goat anti-humanChimeric bispecific MAb-targeted T cells lyse renal carcinoma cells
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IgG (H +L) as secondary antibody (1:1000, Jackson
ImmunoResearch Laboratories). Binding of secondary anti-
body was detected by incubation at room temperature for
30 min with 1 Mg ml-' p-NPP phosphatase substrate solution
(100 pl per well, Sigma 104 substrate tablets in sterile saline
supplemented with 0.2% alkaline buffer solution, Sigma, St
Louis, MO, USA). The reaction was terminated by adding
50 ,ul per well 3 M sodium hydroxide and the optical density
(OD) at 410 nm was recorded in an ELISA plate reader
(Dynatech, Chatilly, VA, USA). Purified chimeric antibody
of the IgGI isotype was used for a standard curve to
calculate the antibody concentration in the samples. Anti-
idiotype G250 MAb (clone NUH-9, obtained from Dr E
Oosterwijk, 0.25 pg per well) was used in ELISA as coating
antibody for the detection of chimeric G250 and bispecific
antibody.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
mRNA was isolated from 3 x 106 cells using the Micro-Fast
Track mRNA isolation kit (Invitrogen, Leek, The Nether-
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lands) according to instructions supplied and was subse-
quently dissolved in 10 pl of sterile water. Per cell line 1 MI of
mRNA was converted into cDNA by reverse transcription
using the cDNA Cycle kit (Invitrogen) in 20 M1 reaction
volume. For PCR on the cDNA, primer sets were designed,
specific for the variable regions of heavy and light chains of
the anti-CD3 and G250 MAb respectively (Pharmacia
Biotech, Roosendaal, The Netherlands). The human Cy
primer, 5'-GGGGAAGACCGATGGGCCCTTGGT-3', de-
rived from the DNA sequence of the human constant region
for IgG, is a universal primer for the human IgG heavy chain
constant region. This primer was used as 3' primer in
combination with either the CD3VH primer, 5'-CAGGTC-
CAACTCCTGCAGTC-3' or the G250VH primer, 5'-
GGGGGAGGCTTAGTGAAGCT-3' as 5' primer for
specific amplication of, respectively, the anti-CD3 or G250
antibody heavy chain. PCR reactions with these primers were
performed in a buffer containing 60 mM TrisHCl, 15 mM
ammonium sulphate and 1.5 mm magnesium chloride (pH
8.5) at an annealing temperature of 58°C. An aliquot of 2 pl
of the reverse transcriptase reaction mixture was used per
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Figure 2 Flow cytometric analysis of chimeric bispecific MAb in culture supematant of transfectants. HPB-ALL T cells were incubated
with culture supernatant of transfection T3 no. 36.4 (white) or PBS (black) followed by incubation with either anti-idiotype G250 MAb and
FITC-labelled goat anti-murine IgGl MAb (a) or FITC-labelled goat anti-human IgG MAb (b). c, Control incubations of HPB-ALL T cells
with chimeric G250 (black), chimeric anti-CD3 MAb (grey) or bispecific G250/OKT-3 F(ab)2 fragments (white), followed by an incubation
with anti-idiotype G250 MAb and FITC-labelled goat anti-murine IgGI MAb. d, Control incubations with chimeric G250 (black), chimeric
anti-CD3 MAb (white) or bispecific G250/OKT-3 F(ab)2 fragments (grey), followed by an incubation with FITC-labelled goat anti-human
IgG MAb.
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PCR reaction. For kappa light chain amplifications the
human CK5' primer, 5'-GATGGGTGACTTCGCAGGCG-3',
derived from the DNA sequence of the human kappa chain
constant region, was used in combination with either the
CD3VK 3' primer, 5'-GTCTGCATCTCCAGGGGAGA-3' or
the G250VK 3' primer, 5'-CAGTAGGAGACAGGGT-
CAGG-3' at an annealing temperature of 55°C. The anti-
CD3 kappa chain was amplified in the buffer described for
the heavy chain PCR; the G250 kappa chain PCRs were
performed in a buffer containing 60 mM Tris-HCl, 15 mM
ammonium sulphate, 2 mM magnesium chloride, pH 9.5. All
primers were used at a final concentration of 50 ng 25 pl-1 in
25 dl PCR reaction volume. Thirty cycles of 1 min melting at
94°C, 1.5 min annealing and 2.5 min elongation at 72°C,
were performed per reaction. PCR products were visualised
by performing 2% agarose gel electrophoresis and staining
the gel with ethidium bromide.
Flow cytometry
The presence of chimeric bispecific antibody in the culture
supernatant of the transfectants was analysed by flow
cytometry. Aliquots of 5 x 105 HPB-ALL T cells were
incubated with 50 pl spent culture supernatant at 4°C for
1 h. Concentrated spent culture supernatant of a chimeric
G250-producing transfectant, purified chimeric anti-CD3
MAb, murine G250 MAb and murine bispecific G250/
OKT-3 F(ab)2 fragments (van Dijk et al., 1989) were used
as controls at concentrations of 20 ug ml-1 IgG in a final
volume of 100 ,ul. After two washes cells were incubated with
either 40 Mg ml-1 anti-idiotype G250 MAb (NUH-9) or
20 ig ml-' goat anti-human IgG, FITC-labelled, for 1 h.
Bound anti-idiotype G250 MAb was stained with FITC-
labelled goat anti-murine IgG1, heavy chain specific.
Incubations with FITC-labelled antibodies were performed
in the dark. Cells were washed twice, resuspended in 500,l
PBS and analysed on a FACscan (Becton Dickinson
Immunocytometry Systems, San Jose, CA, USA). RCC cell
lines were stained for G250 antigen expression using murine
G250 IgGI, which was subsequently detected with goat anti-
murine IgG labelled with FITC. Dead cells were stained with
propidium iodide and were excluded from analysis.
microtitre plates (Greiner, Langenthal, Switzerland). Serial
10-fold dilutions of antibody were added in concentrations
ranging from 1 jug ml-' to 1 ng ml-'. The plates were then
centrifuged at 800 r.p.m. for 2 min and incubated at 37°C for
4 h. An aliquot of 100 ,ul supernatant was counted in an
LKB gamma counter (ER, experimental release). Sponta-
neous release (SR) and maximal release (MR) were assayed
by respectively adding medium or 100 jl of 10% Triton X-
100 to the labelled targets. The percentage specific lysis was
calculated as (ER-SR/MR-SR) x 100%.
Results
Generation of chimeric bispecific G250/anti-CD3 MAb
Chimeric heavy and light chain genes of anti-CD3 MAb were
transfected into P3X63Ag8.653 myeloma cells, yielding
transfectants producing chimeric anti-CD3 MAb, as was
determined by ELISA. The transfectant that had produced
the highest amount of antibody (25 ig per 106 cells) during a
10 day culture, was selected and retransfected with the
expression vector containing the chimeric heavy and light
chain genes of the G250 MAb (Figure 1). The presence of
antibodies with G250 specificity in the culture supernatant of
the transfectants was analysed by ELISA using plates coated
with anti-idiotype G250 MAb and goat anti-human IgG
MAb as detecting antibody as described in Materials and
methods. Twenty transfectants that produced antibodies with
G250 specificity were selected for analysis of bispecific G250/
anti-CD3 MAb production.
The production of chimeric bispecific antibody was
analysed by flow cytometry using HPB-ALL T cells, which
express the CD3 antigen. HPB-ALL T cells were incubated
with culture supernatant of the transfectants followed by the
incubation with anti-idiotype G250 MAb (Figure 2a).
Control incubations of HPB-ALL T cells with only anti-
idiotype G250 MAb revealed that the anti-idiotype G250
MAb did not react with the HPB-ALL cells, and therefore
Antibody purification
T3 no. 36.4 cells, producing chimeric bispecific G250/anti-
CD3 MAb, were cultured in a 1- 1.5 1 culture volume and
the supernatant was concentrated ten times using a ProVario-
3 filter system with a 70 kDa membrane cassette (Filtron
Technology, Terheijden, The Netherlands). Chimeric IgGI
was purified from the concentrated supernatant on a protein
A-Sepharose column using 0.1 M citrate buffer at pH 3.0 for
antibody elution. The bispecific antibody fraction was
separated from parental antibody by high pressure liquid
chromatography (HPLC) on Mono S-Sepharose using a
sodium chloride gradient from 0 to 0.2 M in 25 mM sodium
acetate, pH 5.0, a matrix and procedure that had previously
been described (van Ravenswaay Claasen et al., 1993;
Warnaar et al., 1994; van Dijk et al., 1989).
Cytotoxicity assays
Approximately 2 x 105 target cells were labelled with 50 p,Ci
of [5'Cr]sodium chromate in saline (Amersham, Buckingham-
shire, UK) for 60-90 min at 37°C. The cells were washed
twice and were resuspended in culture medium at
2 x 104 ml- . The human CD3+CD8+T cell clone, TIL 7.9,
was used as effector cells after 7 days of culture.
Alternatively, human peripheral blood lymphocytes (PBLs)
from healthy donors preactivated by culturing in RPMI-1640
with 10% human AB serum and 100 U ml-' IL-2 for 6 days,
were taken as effector cell population. Aliquots of 2000 target
cells were mixed with effector cells at effector-target ratios
ranging from 100: 1 to 12: 1 in 96-well round bottom
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Figure 3 Cytotoxicity of cloned human T cells mediated by
chimeric bispecific MAb. The human T cell clone, TIL 7.9, was
assayed for cytotoxicity against A704 targets in the absence of
antibody (Ol), in the presence of 50,il per well culture supernatant
containing murine bispecific G250/OKT-3 ( ) or 50td per well
culture supernatant containing chimeric bispecific G250/anti-CD3
MAb (_). E/T ratio (effector-target ratio), 2000 targets per
well. Results are presented as percentage specific51Cr release+s.d.
of triplicate cultures in a 4h assay. Data shown are representative
ofthree independent experiments. At all E/T ratios the percentage
lysis in the presence of antibody differs significantly from the
control (P<0.0001).was suitable to detect bispecific antibodies bound to the
HPB-ALL T cells. This was confirmed by positive control
stainings with murine bispecific G250/OKT-3 (anti-CD3)
MAb (Figure 2c). Chimeric G250 MAb did not react with
HPB-ALL T cells, as analysed with the anti-idiotype G250
MAb. A low level of cross-reactivity of the anti-idiotype
G250 MAb with the anti-CD3 MAb was observed (Figure
2c). Culture supernatant of several transfectants showed an
increase in fluorescence as compared with the control
incubations of HPB-ALL T cells without culture super-
natant, indicating that these transfectants produced anti-
bodies with both G250 and anti-CD3 specificity (Figure 2a).
In parallel, HPB-ALL cells, incubated with culture super-
natant or control antibodies, were stained with goat anti-
Chimeric bispecific MAb-targeted T cells lyse renal carcinoma cells
RM Luiten et al $
739
human IgG MAb as detecting antibody to determine the
total amount of antibodies with anti-CD3 specificity present
in the culture supernatant of the transfectants (Figure 2b and
d).
Subsequently, the capacity of culture supernatant of the
transfectants producing chimeric bispecific cG250/anti-CD3
MAb to trigger activated human CD8+T cells for lysis of
target cells that express the G250 antigen was analysed in a
cytotoxicity assay. Figure 3 shows the results of supernatant
of transfectant T3 no. 36.4. The chimeric bispecific G250/
anti-CD3 MAb greatly increased the lysis of A704 target byw
activated T cells, as was observed for the control murine
bispecific G250/OKT-3 (anti-CD3) MAb at effector-target
ratios ranging from 50: 1 to 6: 1.
T cells
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Figure 4 Binding ofHPLC-purified chimeric bispecific MAb to human T cells and RCC cells. Approximately 5 x 105 human T cells
of clone TIL 7.9 orA704 renal carcinoma cells were stained with the HPLC fraction corresponding to peak 1 (c and d) or peak 2 (e
and f, 10 jOgml-) or PBS (a and b), followed by an incubation with FITC-labelled goat anti-human IgG and analysed by flow
cytometry. (a, c and e) antibody binding to T cells; (b, d and f) antibody binding to A704 cells.
a
160
140
120
100
80
60
40
20
a)
en z m E
z
160
140 -
120 -
D1oo-
a) M 80 o- z
60-
40-
20-
160-
140 -
120-
CN 0) 100-
c~gE -
c = 80-
60-
40-
20-
i I
IChimeric bispecific MAb-targeted T cells lyse renal carcinoma cells
RM Luiten et al
740
-Z' 50
40
LO 30
20
10*
10
1 0.1 0.01 0.001 0
MAb concentration (,ug ml-)
Figure 5 Cytotoxicity of cloned human T cells mediated by
HPLC fractions of chimeric bispecific MAb. HPLC peak 1 (OI)
and peak 2 (M) of the chimeric bispecific MAb purification were
assayed for their capacity to mediate cytotoxicity by the human T
cell clone, TIL 7.9, against A704 targets in a 4h"Cr release assay.
Antibody was added to the wells at final concentrations of 1, 0.1,
0.01 or 0.00l yigml- No antibody was added to the control
assays. E/T ratio 25:1, 2000 targets per well. Data shown are
representative of three independent experiments. The percentage
lysis at 1, 0.1 and 0.01 igmlV of peak 2 differs significantly from
peak 1 (P<0.0002).
Purification of chimeric bispecific MAb
Antibody production by transfectant T3 no. 36.4 was
considered stable, since 100% of the clones, obtained by
limiting dilution cloning of a 4 week culture of the
transfectant, produced functional bispecific MAb. The
transfectant produced up to 17 jug ml-1 of total antibody
in spent culture, as measured by ELISA. The percentage of
bispecific MAb was approximately 20-25%. This transfec-
tant was chosen for preparative scale antibody purification.
All possible antibody variants, resulting from random
association of the two types of heavy and light chains
produced by the transfectants, were of IgGI subtype, and
therefore cannot be segregated by affinity purification on
Protein-A Sepharose, which is based on differences in
binding strength of the various subclasses of IgG. There-
fore, total chimeric IgGI was purified from culture
supernatant on Protein A Sepharose and subsequently
separated into individual antibody fractions by HPLC on
Mono S-Sepharose. HPLC analysis of the purified chimeric
IgGI pool produced by transfectant T3 no. 36.4 revealed
only two peaks. The position of one peak in the HPLC
chromatogram was consistent with that of parental G250
antibody (peak 1). The second peak did not resemble
chimeric anti-CD3 MAb and might contain the bispecific
antibody fraction (peak 2). To confirm that peak 2
contained bispecific MAb and peak 1 parental G250 MAb,
cytotoxicity assays were performed and the binding to G250
antigen-expressing tumour cells and T cells was evaluated.
Binding of chimeric bispecific MAb to T cells and tumour cells
The antibody fractions corresponding to the different peaks
in the HPLC chromatogram were analysed for binding to T
cells and A704 cells expressing the G250 antigen. The
human T cell clone, TIL7.9, and A704 cells were incubated
with the antibody fractions corresponding with peak 1 or
peak 2 respectively, and analysed by flow cytometry. Figure
4 shows that antibody of peak 2 reacted with both A704
cells and T cells, while antibody of peak 1 only bound to
A704 cells.
Cytotoxicity of cloned human T cells mediated by chimeric
bispecific MAb
Both antibody fractions (peaks 1 and 2) of the HPLC
separation of the chimeric bispecific MAb were then analysed
for their ability to mediate cytotoxicity by human T cells
against G250 antigen-positive target cells. The antibody
fraction of peak 2 was capable of mediating lysis of A704
target cells, whereas peak 1 antibody was not (Figure 5).
Induction of lysis mediated by peak 2 (cG250/anti-CD3) was
still detectable at an antibody concentration of 0.01 ig ml-'
(Figure 5), which shows that bispecific antibody-mediated
cytotoxicity is effective at low doses of antibody.
Tumour cell lines that did not express the G250 antigen
were not lysed in the presence of the bispecific antibody. The
chimeric bispecific MAb mediated lysis of target cells with a
relatively low expression of the G250 antigen as well as
targets with a higher expression of the G250 antigen (Figure
6). The efficiency of lysis of G250-expressing cells, induced by
chimeric bispecific MAb, was dependent on the concentration
of the bispecific MAb as well as on the target cell line used.
As low levels of G250 expression on T cells might lead to
cytokine release and autokill of T cells by the chimeric
bispecific G250/anti-CD3 MAb, we have tested TNF-a
release by T cells in the presence of the chimeric bispecific
MAb, using the WEHI assay (Luiten et al., 1996). No TNF-oa
release was seen at concentrations of 0.1 jug ml-' bispecific
MAb or parental G250 MAb, whereas chimeric anti-CD3
MAb did lead to TNF-a release.
Based on the binding specificities of both antibody peaks
and the difference in capacity to induce cytotoxicity by T
cells, peak 2 was considered to contain chimeric bispecific
G250/anti-CD3 MAb.
Analysis of mRNA expression for antibody heavy and light
chains
In the chromatogram of the HPLC separation of the chimeric
bispecific antibody fractions a third peak, representing the
parental anti-CD3 MAb, was absent. This might indicate that
one of the chains for the anti-CD3 MAb was not produced
by clone T3 no. 36.4, inhibiting the production of parental
anti-CD3. Therefore, the presence of anti-CD3 andG250
MAb heavy and light chain mRNA in the chimeric bispecific
MAb-producing transfectant, T3 no. 36.4, was determined by
RT-PCR using primer sets specific for the variable regions
of the G250 or the anti-CD3 MAb heavy and light chains.
The parental cell line and cell lines producing either chimeric
anti-CD3 MAb or chimeric G250 MAb were used as control
cell lines to check the specificity of the primers. Figure 7
shows that the primer sets specific for the variable regions of
anti-CD3 MAb heavy and light chains generated a PCR
product of mRNA derived from the anti-CD3 MAb-
producing cell line as well as of mRNA derived from the
chimeric bispecific-producing clone, T3 no. 36.4, indicating
that the transfectant contains mRNA for both anti-CD3
antibody chains. In the control experiment these primer sets
did not yield a PCR product with the G250 MAb-producing
cell line not containing anti-CD3 MAb mRNA. Analogous
results were obtained in analyses for the G250 antibody
mRNA. From both the G250 MAb-producing cell line and
the clone T3 no. 36.4 a PCR product was obtained with
primer sets specific for either the heavy or light chain variable
regions of G250 MAb, and not from the anti-CD3 MAb-
producing cell line. Clone T3 no. 36.4 appeared to contain
mRNA for heavy and light chains of both the anti-CD3 and
the G250 MAb, indicating that all chains transfected were
expressed in clone T3 no. 36.4.
Cytotoxicity ofhuman PBLs mediated by the chimeric
bispecific MAb
Bispecific antibody-mediated cytotoxicity in vivo will deal with
lymphocytes ofvarious phenotypes as effector cell population.Chimeric bispecific MAb-targeted T cells lyse renal carcinoma cells
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Figure 6 Lysis of RCC cell lines by cloned human T cells in the presence of chimeric bispecific MAb. The RCC cell lines, A704,
SK-RC-1, SK-RC-7, SK-RC-45 and ACHN were stained for G250 expression and analysed by flow cytometry (a and b). TIL7.9
cells were assayed for cytotoxicity against A704 (0), SK-RC-1 (0), SK-RC-7 (+), SK-RC-45 (A) and ACHN (-) in the
presence of 1, 0.1, 0.01, 0.001 or 0 pgml-
1 chimeric bispecific G250/anti-CD3 MAb, E/T ratio 25:1, 2000 targets per well (c). d,
G250 antigen expression of RCC cell lines.a Mean channel number (MCN) after subtraction of autofluorescence.
To show that our chimeric bispecific antibody is capable of
inducing lysis by a heterogenous population of lymphocytes,
peripheral blood lymphocytes (PBLs) ofdifferent donors were
used as effector cells. Since chimeric bispecific MAb was unable
to induce cytotoxicity with unstimulated PBLs or with PBLs
after an overnight stimulation with 100 U ml-' IL-2 (van
Ravenswaay Claasen et al., 1993), PBLs were cultured with
100 U ml-' IL-2 for 6 days before cytotoxicity assays. Figure 8
shows that the chimeric bispecific G250/anti-CD3 MAb
induced significant lysis ofA704 targets with PBLs from donor
A or donor C compared with controls without antibody,
whereasPBLsfromdonorBshowed amarginalenhancementof
lysis. Parental chimeric anti-CD3 MAb and G250 MAb do not
mediate cytotoxicity ofactivated PBLs at the concentration of
1 ig ml-' (data not shown). Activation ofPBLs from donorA,
but not donor B, enhanced the level oflysis ofSK-RC-7 target
cells mediated by chimeric bispecific G250/anti-CD3 MAb
(data not shown). The amount oflyticactivity that was induced
in a 4 h incubation varied between donors (van Ravenswaay
Claasen et al., 1993). This might be owing to differences in the
percentage of CD8' cells among the IL-2-stimulated PBLs.
Flow cytometric analysis revealed that PBLs from donor A
indeed contained more CD8+T cells (45%) than PBLs from
donor B (24%). These results show that IL-2-activated PBLs
can be triggered to lyse G250 antigen-positive RCC target cells
in the presence ofbispecific cG250/anti-CD3 MAb.
Discussion
Renal cell carcinoma has been studied intensively to evaluate
different approaches to immunotherapy. Phase I and II
clinical trials in which patients with RCC were treated with
IL-2 revealed the susceptibility of RCC to IL-2, but also
snowed the toxicity of this cytokine when administered
systemically in high doses. IL-2-based therapy is therefore
limited by maximum tolerated dose (Gaynor et al., 1990).
The response rates between these trials varied between 12 and
30% (Marumo et al., 1989; Hayat et al., 1991; Jensen et al.,
1990; Whitehead et al., 1990; Rosenberg et al., 1989), but
occasionally no responses were observed (Abrams et al.,
1990). Co-administration of lymphokine-activated killer
(LAK) cells (Parkinson et al., 1990; Fisher et al., 1988;
Foon et al., 1992; Palmer et al., 1992) or tumour-infiltrating
lymphocytes (TILs) from RCC (Bukowski et al., 1991) did
not result in a significantly better response rate. Several other
cytokines, such as interferon (IFN)-oc (Muss et al., 1987;
Feruglio et al., 1992), IFN-,B and IFN-y (Ernstoff et al.,
1992), have been studied for anti-tumour effects in RCC
patients. Clinical data of IFN-# treatment combined with IL-
2 suggest a better response rate than obtained with IFN-f or
IL-2 therapy alone (Krigel et al., 1990). These clinical data
show that RCCs are responsive to immunotherapy, but that
the anti-tumour effects ofcytokines are limited by the toxicity
of the therapy used.
Directing effector cells towards the tumour by using
bispecific antibodies is a method to increase the specificity
of the effector cell population for the targeted tumour cells.
Such bispecific MAbs have been demonstrated to induce
effective lysis of tumour cells in vitro. Limited patient studies
showed localisation of bispecific antibody-targeted effector
cells to the tumour and cross-linking of effector cells with
tumour cells (Kroesen et al., 1993). A study ofintraperitoneal
treatment of ovarian carcinoma with the bispecific OC/TR
MAb which recognises both the carcinoma-associated antigen
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Figure 7 Analysis of antibody heavy and light chain mRNA of
the anti-CD3 and G250 MAb. RT-PCR reactions using primer
sets specific for the anti-CD3 and G250 MAb heavy (HC) and
light chains (LC) were performed on mRNA isolated from (1) the
untransfected cell line, P3X63Ag8.653 (2); the cell line 4B5
producing chimeric anti-CD3 MAb (3); chG250 7C1 producing
chimeric G250 MAb; and (4) the transfectant T3 no. 36.4. The
pictures show an ethidium bromide staining of the PCR products
electrophoresed on a 2% agarose gel.
MOv18 expressed on ovarian carcinoma and the CD3
complex on T cells, resulted in several cases of tumour
regression (Bolhuis et al., 1992; Canevari et al., 1995).
The G250 antigen is an attractive target for antibody-
mediated therapy, because of its nearly exclusive expression
in renal carcinoma cells. Studies with the G250 MAb and the
murine bispecific G250/OKT-3 (anti-CD3) MAb have shown
preferential localisation of these antibodies to the tumour
(Oosterwijk et al., 1993; van Dijk et al., 1991) and anti-
tumour effects in RCC-xenografted nude mice (van Dijk et
al., 1994). The G250/anti-CD3 MAb was chimerised to
decrease immunogenicity of the bispecific antibody in
patients, because studies in patients with murine anti-tumour
antibodies and bispecific antibodies are limited by the
development of HAMA responses. These limitations may
be greatly reduced by using chimeric antibodies for therapy
(LoBuglio et al., 1989; Meredith et al., 1991). A chimeric
bispecific G250/anti-CD3 MAb provides the possibility of
performing patient studies, in which multiple doses of the
bispecific antibody can be administered over a long treatment
period hopefully resulting in more extensive tumour
regression.
We generated a cell line that produces chimeric bispecific
G250/anti-CD3 MAb stably by supertransfection of a cell
line producing chimeric anti-CD3 MAb with a single
expression vector encoding both chimeric heavy and light
chains of the G250 MAb. The chimeric bispecific G250/anti-
CD3 MAb produced by the supertransfected cells, was
demonstrated to bind both to G250-expressing RCC cells
and to human T cells. Chimeric bispecific G250/anti-CD3
MAb is capable of mediating lysis of G250 antigen-positive
RCC cells by cloned human CD8+T cells at concentrations
as low as 0.01 ug ml-'. Tumour cells with a relatively low
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Figure 8 Cytotoxicity of IL-2-activated human PBL mediated by
chimeric bispecific MAb. PBLs from three donors, preactivated
with 10OUml-' IL-2 for 6 days, were assayed for cytotoxicity
against the RCC cell line A704 in the presence or absence of
1 jigml-l purified chimeric bispecific G250/anti-CD3 MAb. At
2000 targets per well, (L ) E/T ratio 100: 1, without MAb;
(w) E/T ratio 50: 1, without MAb; (m) E/T ratio 100: 1, with
MAb; (_) E/T ratio 50:1, with MAb. Data shown are
representative of three independent experiments. The percentage
lysis observed for donor A (P<0.0001) and C (P<0.02) in the
presence of MAb differ significantly from the controls. Donor B
(E/T ratio 50: 1), P<0.02.
expression of the G250 antigen were shown to be lysed
equally as well as tumour cells with a high G250 antigen
expression.
The chromatogram of the HPLC analysis of the antibody
pool produced by clone T3 no. 36.4 revealed only two sharp
and symmetrical peaks. One peak (1) corresponded to the
chromatogram of G250 MAb and the other peak (2)
represented the bispecific antibody fraction. The absence of
a third peak representing parental anti-CD3 MAb was not
the result of the loss of either the anti-CD3 MAb heavy or
light chain, since RT-PCR analysis showed the presence of
mRNA for all four antibody chains. The chromatographic
separation method has been used previously to purify
bispecific OVTL3/OKT-3 MAb (van Ravenswaay Claasen
et al., 1993), murine bispecific OC/TR (Warnaar et al., 1994),
chimeric bispecific OC/TR (Coney et al., 1996) and murine
bispecific G250/OKT-3 MAb (van Dijk et al., 1989), and was
shown to separate all combinations of heavy and light chains
into distinguishable peaks. Therefore, we expect peak 2 of the
chimeric G250/anti-CD3 MAb separation to contain IgG
molecules composed of the parental heavy and light chains.
We have no data to exclude mismatches in peak 2. However,
De Lau et al. (1991) have shown that the production of two
types of heavy and light chains by a quadroma does not
necessarily lead to random association of these chains.
Depending on the combination of parental antibodies,
preferential association of heavy and light chains may
occur, resulting in the absence of some heavy and light
chain combinations. In addition, the profiles of the
chromatograms of different clones producing the same
bispecific OC/TR MAb have been shown to differ greatly,
as a result of different rates of synthesis of the antibody
chains (Warnaar et al., 1994). In both the murine OC/TR-
producing hybridoma and the chimeric OC/TR-producing
hybridoma, clones were found that produced only one
parental antibody and the bispecific MAb. The chromato-
gram of clone T3 no. 36.4 therefore represents one of the
variants of the chromatograms that were observed among
different clones producing other bispecific MAbs.
For any RCC patient to be treated with chimeric bispecificChhurs V_i.dk t _~gsd T cls lysT ruui wcuiuu cels
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G250/anti-CD3 MAb, the effector cell population to be
activated will be a T cell ofvariable phenotype residing in the
PBLs. IL-2-activated PBLs can be activated in vitro by
chimeric bispecific G250/anti-CD3 MAb to lyse G250
antigen-expressing RCC cells. The activated PBL cytotoxi-
city may vary between donors and may vary according to the
activation protocol (van Ravenswaay Claasen et al., 1993).
The in vitro cytotoxicity data suggest that treatment of RCC
patients with chimeric bispecific G250/anti-CD3 MAb
requires preactivation of the patients PBLs. Activated PBLs
can be administered to the patient in combination with
chimeric bispecific G250/anti-CD3 MAb, or altematively IL-
2 can be given as in current IL-2-based regimens and
bispecific G250/anti-CD3 MAb can be co-administered to
enhance the effectiveness of IL-2-based therapy.
The murine versions of G250 and anti-CD3 MAb were
immunogenic in patients, which was not the case for the
chimeric versions (Dr E Oosterwijk, personal communication,
Coney et al., 1996; Oosterwijk et al., 1993; Canevari et al.,
1995). Since the components of the chimeric bispecific G250/
anti-CD3 MAb did not induce an immune response, it is
reasonable to expect that the chimeric bispecific MAb will
also be non-immunogenic. Although humanisation of
antibodies through CDR grafting is generally assumed to
reduce immunogenicity further compared with chimeric
antibodies, there is no solid patient data to support this
notion. Humanised and chimeric antibodies have reduced
immunogenicity compared with murine antibodies, however
no direct comparison between humanised and chimeric MAbs
has been performed. The fact that chimerisation of the G250
and anti-CD3 MAbs apparently abrogates the patients'
immune response to the infused antibody, makes humanisa-
tion of the antibodies unnecessary. It is likely that any
residual immunogenicity ofchimeric or humanised antibodies
will be idiotype dependent.
In conclusion, the chimeric bispecific G250/anti-CD3 MAb
may represent a useful tool for enhancing the results obtained
in RCC treatment using IL-2.
Abb
MAb, monoclonal antibody; RCC, renal cell carcinoma; HAMA,
human anti-mouse antibody; VH, variable region of antibody
heavy chain; VK, variable region of antibody kappa chain; CH,
constant region of antibody heavy chain; CK, constant region of
antibody kappa chain; gpt, xanthine guanine phosphoribosyl
transferase; neo, neomycin; RT-PCR, reverse transcriptase -
polymerase chain reaction.
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